CURRICULUM VITAE

GREGORY JAMES FERREIRA M.D., FCCP

Business address: **Premier Physicians of Sarasota**
1843 Floyd Street
Sarasota, FL
Phone: 941.951.3920
Fax: 941.951.3922
2014 – Present
Previously DBA
Hautamaki & Horiuchi
Personal Physicians of Sarasota

Prior business address: Lung Associates of Sarasota
1921 Waldemere Plaza
Suite 705
Sarasota, FL
Phone: 941.366.5864
Fax: 941.365.4276

Hospital Affiliation: **Sarasota Memorial Hospital**
1700 S. Tamiami Trail
Sarasota, FL
Phone: 941.917.9000

Present position: Physician, Private Practice

Faculty Appointment: Clinical Assistant Professor, Department of Clinical Sciences (Internal Medicine, Pulmonary & Critical Care Medicine), Florida State University College of Medicine

Education:

Pulmonary and Critical Care Fellowship, Winthrop University Hospital
Mineola, New York
July 2002 to June 2005

Internal Medicine Internship and Residency, Winthrop University Hospital
Mineola, New York
July 1999 to June 2002

Doctor of Medicine, St. Georges University School of Medicine
Grenada, W. I.
January 1995 to June 1999

Bachelor of Science, University of Florida
Gainesville, Florida
July 1990 to June 1994

Medical Licensure Certification:

Florida State Board of Medicine License
American Board of Internal Medicine: Board Certified Internal Medicine -2002
American Board of Medicine: Board Certified Pulmonary Medicine -2004
American Board of Medicine Board Certified Critical Care Medicine-2005
Diplomate American Board of Sleep Medicine-2006
United States Medical Licensing Exam I-III

Cliinical Activity:

Staff Physician, Sarasota Memorial Hospital, Sarasota, FL, 2005 to present
Staff Physician, HealthSouth Rehabiliation Hospital of Sarasota 2005 to present
Staff Physician, Complex Care Rehabilitation Hospital 2005 to present
Medical Director, Sleep Center of Sarasota 2009 to present
Pulmonologist, MDA Clinic Sarasota, FL 2008 to present
Special Care (ICU) Committee, Sarasota Memorial Hospital, 2005 to present
Medical Executive Committee Sarasota Memorial Hospital 2013

Organizations:

American Medical Association
American Thoracic Society
American College of Chest Physicians
Iota Epsilon Alpha Honor Society

Publications:

Ferreira GJ, Trow TK. What Is the Optimal Fluid for Volume Resuscitation? Clinical Pulmonary Medicine. 2005; 12(3):197-199.

Ferreira GJ, Trow TK. Confusion Over Delerium: Does It Predict Death in the Intensive Care Unit? Clinical Pulmonary Medicine. 2005;11(6):387-88

Ferreira GJ, Trow TK, Ragolia L, Edelman M, Hurewitz A, Pulmonary Vasculopathy and PGD_2 Synthase Expression. *ATS 2005 Accepted Poster*

Ferreira, GJ, Spiegler P. Results of an 8-week, outpatient pulmonary rehabilitation program on patients with and without chronic obstructive pulmonary disease. *J Cardiopulm Rehabil.* 200;26(1):54-60.

Ferreira GJ, Trow TK. Chemotherapy After Surgery For Non-Small Cell Lung Cancer: Should It Be Given? *Clinical Pulmonary Medicine.* 2004;11(3):191-192

Ferreira GJ, Trow TK, Hurewitz A. Circulating Prostaglandin D2 Synthase (PGD2) Levels in Pulmonary Hypertension. *ACCP 2005 Poster*

Ferreira GJ, Spiegler P. The Benefits of Pulmonary Rehabilitation in Patients without COPD. *ATS 2004 Accepted Abstract and Poster Presentation*

Ferreira GJ, Spiegler P. Oral Prednisone for Outpatient Chronic Obstructive

Pulmonary Disease Exacerbations. *Clinical Pulmonary Medicine*. 2003;10(6):346-347

Ferreira GJ, Trow TK. Warfarin Loading: Does it make sense? *Clinical Pulmonary Medicine*. 2003;10(5):295-296

Ferreira GJ, Spiegler P. Glycemic control versus insulin dose in the critically ill.*Clinical Pulmonary Medicine.* 2003;10(4):244-245

Ferreira GJ, Groth M. ARDS management: High Frequency Oscillatory Ventilation as a new option. *Clinical Pulmonary Medicine.* 2003;10:120-121

Ferreira GJ, Della Ratta RK. Fatal Diverticulitis with serial negative CT scans. *ACP-ASIM accepted Abstract Competition Presentation 2001*

Clinical Research:

020-A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient, Safety and Efficacy Study of TAK-375 in Adults with Chronic Insomnia

022- A Phase III, Open-Label, Fixed-Dose Study to Determine the Safety of Long Term Administration of TAK 375 in Subjects with Chronic Insomnia

025- A Phase III, Randomized, Double-Blind, Placebo-Controlled, Outpatient, Safety and Efficacy Study of TAK-375 in Elderly Subjects with Chronic Insomnia

Multi-Center Clinical Study of the Bard Silver Coated Endotracheal Tube

A Double-Blind Placebo-Controlled, Parallel Group Phase II Dose-Ranging Study of Nebulized Amikacin Delivered Via the Pulmonary Drug Delivery System (PDDS) in Patients With Ventilator-Associated Pneumonia Due to Gram-Negative Organisms

A Randomized, Double-Blind, Placebo-Controlled Study to Determine the Efficacy And Safety of Epoetin Alfa in Critically Ill Subjects

A Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Five-Arm Parallel-Group Trial To Investigate the Efficacy and Safety of Four Different Transdermal Doses of Rotigotine In Subjects With Idiopathic Restless Legs Syndrome

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). A Randomized, Double-blind Study to Evaluate the Safety and Effectiveness of the Exhale® Drug-Eluting Stent in Homogeneous Emphysema Subjects with Severe Hyperinflation (EASE) (July 2006- Present) SPONSOR: Broncus Technologies, Inc.Protocol 30

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). A Randomized, Double-Blind, Parallel Group Clinical Trial Evaluating The Effect of the Fluticasone Propionate/Salmeterol Combinatino Product 250/50mcg BID via DISKUS versus Salmeterol 50 mcg BID via DISKUS on Bone Mineral Density in Subjects with Chronic Obstructive Pulmonary Disease (COPD)

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Safety and Efficacy of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis

Clinical Research (con't)

(May 2006- December 2008)

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). A Phase IIB, 12-Month, Double-blind, Double-dummy, Randomised, Parallel-group, Multicentre Exacerbation Study of SYMBICORT® pMDI 160/4.5 ug x2 Actuations Twice-daily and 80/4.5 ug x2 Actuations Twice-daily Compared to Formoterol TBH 4.5 ug x2 Inhalations Twice-daily in COPD Subjects

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). A Prospective, Controlled, Multicenter Clinical Trial to Evaluate the Safety and Effectiveness of the IBV® Valve System for the Treatment of Severe Emphysema (October 2007-Present)

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). Continued Access Treatment Protocol with the IBV® Valve System for Severe Emphysema (November 2008-Present)

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). An Open-Label Extension Study of the Long-term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis Who Complete the CAPACITY Studies (March 2008-Present)

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). A Phase 3, Multi-Center, Open Label Study To Evaluate The Longterm Safety Of Monotherapy Sitaxsentan Sodium And Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension (Aug 2008- Present)

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). A Phase 3, Multi-Center, Randomized, Double-Blind, Efficacy And Safety Study Of Monotherapy Sitaxsentan Sodium Versus Combination Therapy With Sitaxsentan Sodium And Sildenafil Citrate In Subjects With Pulmonary Arterial Hypertension Who Have Completed Study B1321001 (Aug 2008- Present)

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). Title: NAI114373: A Phase III international, randomized, double-blind, double-dummy study to evaluate the efficacy and safety of 300 mg or 600 mg of intravenous zanamivir twice daily compared to 75 mg of oral oseltamivir twice daily in the treatment of hospitalized adults and adolescents with influenza

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/ Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Disease (COPD) and a history of or an increased risk for cardiovascular disease.

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). Protocol GS-US-219-0104 A Phase 3, Double-Blind, Multicenter, Randomized, Placebo-Controlled Trial Evaluating Repeated Courses of Aztreonam for

Clinical Research (con't):

Inhalation Solution/Aztreonam 75 mg Powder and Solvent for Nebuliser Solution in Subjects with non-CF Bronchiectasis and Gram-Negative Endobronchial Infection (AIR-BX2)

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Multi-Center Study to Assess the Efficacy and Safety of GS-6624 in Subjects with Idiopathic Pulmonary Fibrosis (RAINIER) Protocol Number: GS-US-322-0207

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). Protocol Title: A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study of the Efficacy and Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis Protocol Number: PIPF-016

Principle-Investigator (Clinical Research Center of Sarasota Memorial Hospital). HZC113782: A Clinical Outcomes Study to compare the effect of Fluticasone Furoate/Vilanterol Inhalation Powder 100/25mcg with placebo on Survival in Subjects with moderate Chronic Obstructive Pulmonary Diseases (COPD) and a history of or at increased risk for cardiovascular disease

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). A double blind randomized placebo controlled trial evaluating the effect of oral nintedanib 150 mg twice daily on high resolution computerized tomography quantitative lung fibrosis score, lung function, six minute walk test distance and St. George's Respiratory Questionnaire after twelve months of treatment in patients with Idiopathic Pulmonary Fibrosis with continued evaluations over a period of up to eighteen months Fibrosis

Sub-Investigator (Clinical Research Center of Sarasota Memorial Hospital). A Multicentre, Randomised, Double-Blind, Placebo-controlled Phase IIb Study to Compare the Efficacy and Safety of Two Dosing Regimens of Intravenous Infusions of CytoFab™ (AZD9773) in Adult Patients With Severe Sepsis and/or Septic Shock.